Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering

Stock Information for Evofem Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evofem Biosciences Inc.

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
Evofem Biosciences to Present at Emerging Growth Conference
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.